What we do

What does Repertoire Genesis do?

It is implementing a new treatment methodology using immune diversity analysis technology.

By analyzing immunity's "diversity", the mechanism of intractable diseases, which was not understood to date, can be clarified. As a consequence, efficient drug development can take place. Additionally, individually tailored treatment selection is expected.

A business centered on technology will be developed to analyze immunity's "diversity". We are working on the development of new treatments and diagnostic methods for patients suffering from diseases worldwide.

What is immunity's "diversity"?

In the event immune cells identify foreign cells (things other than yourself) such as viruses and bacteria, they protect us by attacking them and removing them from the body.
Of note, just as with measles, once an individual has acquired a disease and he/she will never suffer from it again.

Once we develop measles, we will not develop it again. However, we could develop another disease like mumps.
This is called "specificity" of the immune system.
However, a strong defense mechanism is in place to cope with the not-yet-developed mumps.
This is called immunity's "diversity".

Repertoire Genesis around you

There are numerous settings surrounding us utilizing Repertoire Genesis technology.


It is used for the development of tests for treatment effect prediction.

Food companies

Food companies
It is used for the development of functional foods.


It is used to investigate the cause of uncurable conditions and elucidate pathology of diseases.

Pharmaceutical companies

Pharmaceutical companies
It is used for the development of new drugs and diagnostic tests.


It is used for basic research studies (e.g. identification of novel medicines, diagnostic tests, and cell therapy).


Our Strength

Strengths of Repertoire Genesis

Repertoire Genesis is developing its business based on the following three strengths: "flexibility", "analytical technology", and "intellectual property strategy".

  • POINT - 1Flexibility
  • POINT - 2Analytical Technology
  • POINT - 3Intellectual property strategy

A platform that flexibly responds to customer-specific tasks

A platform provided by a conventional bio-venture company generally targets a research institute (academia) or a pharmaceutical company for a specific task. For example, the task of discovering drug candidates is targeted to a pharmaceutical company.
Our platform can provide individualized flexible services for different tasks. It can target multiple institutions such as universities and other research institutions, pharmaceutical companies, diagnostic drug companies, and medical service providers.

Our analytical technology is applicable to a wide spectrum of diseases such as cancer, autoimmune, infectious, neurological, and metabolic diseases.
For example, our analysis technology for cancer is utilized as follows

"Neo epitope analysis" to locate landmarks and attack cancer cellsSee more

Genes accumulate mutations because of exposure to ultraviolet rays, smoking, or aging.
Therefore, an antigen (neoantigen) that was originally not present in normal cells is newly created in abnormal cells (e.g. cancer cells). Subsequently, immune cells such as T cells recognize the abnormal cells as foreign matter and eliminate it.
Neo epitope is a cancer cell marker. Neoepitopes can activate cytotoxic T cells that attack cancer cells. Therefore, they can be also used for therapeutic purposes.
Our neoepitope analysis allows us to find effective neoepitopes for therapeutic purposes. This is done by comparing the gene sequences in cancerous cells with those in normal tissues of patients.
By utilizing our proprietary analytical algorithms, we can obtain an accurate identification of useful neoepitopes that could not be found by conventional analysis.

"Repertoire Analysis" to Identify T Cells Attacking Cancer CellsSee more

Cytotoxic T cells recognize neo-epitopes not found in normal cells. Additionally, they attack cancer cells using a T-cell receptor (TCR) present on the cell's surface.
However, there are various kinds of T cells in the body. Those capable of specifically recognizing neo-epitopes are only a smaller subset of them.
Our Repertoire Analysis is a technology that can exhaustively investigate TCR genes. We are capable of finding T cells that can respond to patient-specific neo-epitopes from a variety of T cells.
Our Repertoire Analysis algorithm is not biased like other similar conventional algorithms. Additionally, it represents an accurate and reliable method.
For treatment we are attempting to use specific TCR genes and T cells identified by our algorithm.

Intellectual property strategy integrated with business and R&D strategies

Our goal is to create an environment where the fundamental technology of our company and the innovative technologies it applies will constantly evolve.
Therefore, we actively publish the outcomes of the research performed by our company and the joint research conducted in collaboration between our company and academia, laboratories, medical institutions. Additionally, we show the results of our customers' research.

Importantly, we actively secure intellectual property rights for the technology that we have innovated.
We believe that intellectual property strategy is an important management strategy.
Specifically, we manage "intellectual property strategy", "business strategy", and "R&D strategy" as a trinity.
In Japan, we have already acquired patents in the basic technology field.
Furthermore, we apply for patents on technologies necessary for the creation of more effective immunotherapy. In Japan and overseas, we have seven patents in diagnosis/drug discovery and treatment domains.


Toward Further Growth

Enhanced business performance supported by customers

To date we have stable collaboration with Academia. In addition to this, collaborations with pharmaceutical companies and other institutions are also expanding.

Since our establishment in 2014, we have accumulated significant experience in providing services to research institutes such as universities.
In recent years, we have received orders of medium to large projects from pharmaceutical companies following our achievements in academia.

We plan on venturing into novel challenging fields without affecting our growth.


Our Future

Future of Repertoire Genesis

To develop novel cell therapy

Cell therapy is a methodology of treating diseases by using one's own cells or cells from others.
It is attracting attention as a challenging technology to treat diseases difficult to cure by conventional treatment methods.
It is well known for CAR-T cell therapy, which has been used in the USA and Europe.

However, current cell therapy is limited by the expensive treatment costs, efficacy, and safety.

These issues represent our focus. We are working on developing novel technologies and other solutions to overcome these problems.
From now on, with the use of these technologies, we plan on focusing on research, development, and commercialization. Our aim is to develop novel cell therapy which is cheaper, effective, and safe.